Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 5.894
Filtrer
1.
BMC Infect Dis ; 24(1): 906, 2024 Sep 02.
Article de Anglais | MEDLINE | ID: mdl-39223521

RÉSUMÉ

BACKGROUND: Glycopeptides for ampicillin-susceptible Enterococcus faecalis/faecium bacteremia are readily prescribed depending on the severity of the condition. However, there is limited data on the outcomes of glycopeptide use compared to ampicillin-containing regimens for ampicillin-susceptible E. faecalis/faecium bacteremia. From an antibiotic stewardship perspective, it is important to determine whether the use of glycopeptides is associated with improved clinical outcomes in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. METHODS: This retrospective cohort study was conducted at a university-affiliated hospital between January 2010 and September 2019. We collected data from patients with positive blood cultures for Enterococcus species isolates. The clinical data of patients who received ampicillin-containing regimens or glycopeptides as definitive therapy for ampicillin-susceptible E. faecalis/faecium bacteremia were reviewed. Multivariate logistic regression analysis was performed to identify risk factors for 28-day mortality. RESULTS: Ampicillin-susceptible E. faecalis/faecium accounted for 41.2% (557/1,353) of enterococcal bacteremia cases during the study period. A total of 127 patients who received ampicillin-containing regimens (N = 56) or glycopeptides (N = 71) as definitive therapy were included in the analysis. The 28-day mortality rate was higher in patients treated with glycopeptides (19.7%) than in those treated with ampicillin-containing regimens (3.6%) (p = 0.006). However, in the multivariate model, antibiotic choice was not an independent predictor of 28-day mortality (adjusted OR, 3.7; 95% CI, 0.6-23.6). CONCLUSIONS: Glycopeptide use was not associated with improved mortality in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. This study provides insights to reduce the inappropriate use of glycopeptides in ampicillin-susceptible E. faecalis/faecium bacteremia treatment and promote antimicrobial stewardship.


Sujet(s)
Ampicilline , Antibactériens , Bactériémie , Enterococcus faecalis , Glycopeptides , Infections bactériennes à Gram positif , Sulbactam , Humains , Études rétrospectives , Bactériémie/traitement médicamenteux , Bactériémie/microbiologie , Bactériémie/mortalité , Ampicilline/usage thérapeutique , Ampicilline/pharmacologie , Mâle , Femelle , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Enterococcus faecalis/effets des médicaments et des substances chimiques , Infections bactériennes à Gram positif/traitement médicamenteux , Infections bactériennes à Gram positif/microbiologie , Infections bactériennes à Gram positif/mortalité , Sujet âgé , Adulte d'âge moyen , Glycopeptides/usage thérapeutique , Glycopeptides/pharmacologie , Sulbactam/usage thérapeutique , Sulbactam/pharmacologie , Résultat thérapeutique , Tests de sensibilité microbienne , Sujet âgé de 80 ans ou plus
2.
Pharmacol Res Perspect ; 12(4): e1250, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39105353

RÉSUMÉ

Sepsis is a common disease with high morbidity and mortality among newborns in intensive care units world-wide. Gram-negative bacillary bacteria are the major source of infection in neonates. Gentamicin is the most widely used aminoglycoside antibiotic in empiric therapy against early-onset sepsis. However, therapy failure may result due to various factors. The purpose of this study was to identify predictors of gentamicin therapy failure in neonates with sepsis. This was a prospective cross-sectional study at the Neonatal Intensive Care Unit at Windhoek Central Hospital over a period of 5 months in 2019. Neonates received intravenous gentamicin 5 mg/kg/24 h in combination with either benzylpenicillin 100 000 IU/kg/12 h or ampicillin 50 mg/kg/8 h. Logistic regression modeling was performed to determine the predictors of treatment outcomes. 36% of the 50 neonates were classified as having gentamicin treatment failure. Increasing treatment duration by 1 day resulted in odds of treatment failure increasing from 1.0 to 2.41. Similarly, one unit increase in CRP increases odds of gentamicin treatment failure by 49%. The 1 kg increase in birthweight reduces the log odds of treatment failure by 6.848, resulting in 99.9% decrease in the odds of treatment failure. One unit increase in WBC reduces odds of gentamicin treatment failure by 27%. Estimates of significant predictors of treatment failure were precise, yielding odds ratios that were within 95% confidence interval. This study identified the following as predictors of gentamicin therapy failure in neonates: prolonged duration of treatment, elevated C-reactive protein, low birthweight, and low white blood cell count.


Sujet(s)
Antibactériens , Gentamicine , Unités de soins intensifs néonatals , Échec thérapeutique , Humains , Gentamicine/usage thérapeutique , Gentamicine/administration et posologie , Nouveau-né , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Études transversales , Études prospectives , Femelle , Mâle , Unités de soins intensifs néonatals/statistiques et données numériques , Sepsis néonatal/traitement médicamenteux , Protéine C-réactive/analyse , Sepsie/traitement médicamenteux , Sepsie/mortalité , Poids de naissance , Ampicilline/usage thérapeutique , Ampicilline/administration et posologie
3.
Medicine (Baltimore) ; 103(31): e39015, 2024 Aug 02.
Article de Anglais | MEDLINE | ID: mdl-39093751

RÉSUMÉ

RATIONALE: Listeria monocytogenes (LM) is an important foodborne bacterium, and LM meningoencephalitis is rare in clinical practice, with poor prognosis in severe patients. It is prone to misdiagnosis in clinical practice. We first reported a case of severe LM meningoencephalitis with muscle lesions and evaluated the comprehensive condition. PATIENT CONCERNS: A 48-year-old man had a fever and was admitted to the neurology department due to dizziness, nausea, and vomiting for 20 days. DIAGNOSES: LM meningoencephalitis complicated with muscle lesions. INTERVENTIONS: We used moxifloxacin 0.4 g, qd, meropenem 2 g, q8h, and dexamethasone 10 mg, qd to reduce exudation and adhesion. Then due to consideration of side effects, we increased the dose of ampicillin by 2 g, q4h, stopped using meropenem and moxifloxacin, and turned to maintenance treatment with dexamethasone and ampicillin. We comprehensively managed his vital signs and physical organ functions, we also controlled some comorbidities. During the hospitalization period thereafter, we used intravenous anti-infection treatment with moxifloxacin 0.4 g, qd, ampicillin 0.5 g, q4h. OUTCOMES: Half a year later, the reexamination showed only protein elevation in cerebrospinal fluid and hydrocephalus in MRI. Afterward, the symptoms did not recur again. The patient recovered well after discharge. LESSONS: LM meningoencephalitis complicated with lower limb muscle lesions is clinically rare. This report focuses on relevant treatment plans, which provide value for the examination and comprehensive management of patients with LM infection in the future.


Sujet(s)
Antibactériens , Sensation vertigineuse , Fièvre , Nausée , Vomissement , Humains , Mâle , Adulte d'âge moyen , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Fièvre/étiologie , Sensation vertigineuse/étiologie , Vomissement/étiologie , Nausée/étiologie , Méningoencéphalite/traitement médicamenteux , Méningoencéphalite/diagnostic , Méningoencéphalite/microbiologie , Moxifloxacine/usage thérapeutique , Moxifloxacine/administration et posologie , Dexaméthasone/usage thérapeutique , Dexaméthasone/administration et posologie , Listeria monocytogenes/isolement et purification , Ampicilline/usage thérapeutique , Ampicilline/administration et posologie
4.
J Med Case Rep ; 18(1): 390, 2024 Aug 23.
Article de Anglais | MEDLINE | ID: mdl-39175052

RÉSUMÉ

BACKGROUND: Listeria monocytogenes brain abscess is a rare phenomenon that is common in immunocompromised patients. Streptococcus equinus brain abscess has never been reported in the literature to our knowledge. In this case report, we describe a case of brain abscess secondary to Listeria monocytogenes and Streptococcus equinus in an immunocompetent patient with transient low CD4 count. CASE PRESENTATION: A 27-year-old white, male patient, previously healthy, nonalcoholic, and occasional smoker, presented to the emergency department for confusion and headache. The patient was found to have a left parietal abscess, which was drained and the fluid was sent for culture. Culture grew Listeria monocytogenes and Streptococcus equinus. The patient was treated with intravenous ampicillin followed by oral amoxicillin for a total of 6 weeks. The CD4 count was low initially. However, after the resolution of the infection, the CD4 count came back within normal range. Another brain magnetic resonance imaging was done that showed a significantly decreased hyperintensity within the left parietal subcortical white matter at the site of surgery with significantly decreased enhancement and almost total resolution of the previous abscess. CONCLUSION: Transient low CD4 count is a rare phenomenon that exposes patients to unusual and atypical infections. Since low CD4 count is transient, patients treated promptly recover from their illness. Our patient developed a Listeria monocytogenes and Streptococcus equinus brain abscess, which is considered rare and has not been previously described in the literature to our knowledge.


Sujet(s)
Antibactériens , Abcès cérébral , Listeria monocytogenes , Infections à Listeria , Infections à streptocoques , Humains , Mâle , Abcès cérébral/microbiologie , Abcès cérébral/traitement médicamenteux , Listeria monocytogenes/isolement et purification , Adulte , Antibactériens/usage thérapeutique , Infections à streptocoques/traitement médicamenteux , Infections à streptocoques/microbiologie , Infections à streptocoques/diagnostic , Infections à Listeria/traitement médicamenteux , Infections à Listeria/diagnostic , Infections à Listeria/microbiologie , Imagerie par résonance magnétique , Ampicilline/usage thérapeutique , Immunocompétence , Amoxicilline/usage thérapeutique , Amoxicilline/administration et posologie
5.
PLoS One ; 19(7): e0304705, 2024.
Article de Anglais | MEDLINE | ID: mdl-38980858

RÉSUMÉ

This is a protocol for PPROM-AZM Study, phase II, nonblinded, randomized controlled trial. Bronchopulmonary dysplasia (BPD) at a postmenstrual age of 36 weeks (BPD36) is often observed in infants with preterm premature rupture of the membranes (pPROM). A regimen of ampicillin (ABPC) intravenous infusion for 2 days and subsequent amoxicillin (AMPC) oral administration for 5 days plus erythromycin (EM) intravenous infusion for 2 days followed by EM oral administration for 5 days is standard treatment for pPROM. However, the effect on the prevention of moderate/severe BPD36 using the standard treatment has not been confirmed. Recently, it is reported that ampicillin/sulbactam (ABPC/SBT) plus azithromycin (AZM) was effective for the prevention of moderate/severe BPD36 in pPROM patients with amniotic infection of Ureaplasma species. Therefore, our aim is to evaluate the occurrence rate of the composite outcome of "incidence rate of either moderate/severe BPD36 or intrauterine fetal death, and infantile death at or less than 36 weeks 0 days" comparing subjects to receive ABPC/SBT for 14 days plus AZM for 14 days (intervention group) and those to receive ABPC/SBT for 14 days plus EM for 14 days (control group), in a total of 100 subjects (women with pPROM occurring at 22-27 weeks of gestation) in Japan. The recruit of subjects was started on April 2022, and collection in on-going. We also investigate the association between the detection of Ureaplasma species and occurrence of BPD36. In addition, information on any adverse events for the mother and fetus and serious adverse events for infants are collected during the observation period. We allocate patients at a rate of 1:1 considering two stratification factors: onset of pPROM (22-23 or 24-27 weeks) and presence/absence of a hospital policy for early neonatal administration of caffeine. Trial registration: The trial number in the Japan Registry of Clinical Trials is jRCTs031210631.


Sujet(s)
Ampicilline , Antibactériens , Azithromycine , Dysplasie bronchopulmonaire , Érythromycine , Rupture prématurée des membranes foetales , Adulte , Femelle , Humains , Nouveau-né , Grossesse , Amoxicilline/usage thérapeutique , Amoxicilline/administration et posologie , Ampicilline/administration et posologie , Ampicilline/usage thérapeutique , Antibactériens/administration et posologie , Antibactériens/usage thérapeutique , Azithromycine/administration et posologie , Azithromycine/usage thérapeutique , Dysplasie bronchopulmonaire/prévention et contrôle , Dysplasie bronchopulmonaire/traitement médicamenteux , Association de médicaments , Érythromycine/usage thérapeutique , Érythromycine/administration et posologie , Rupture prématurée des membranes foetales/traitement médicamenteux , Âge gestationnel , Japon/épidémiologie , Sulbactam/administration et posologie , Sulbactam/usage thérapeutique , Essais contrôlés randomisés comme sujet , Études multicentriques comme sujet , Essais cliniques de phase II comme sujet
7.
Biomater Adv ; 162: 213931, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-38924805

RÉSUMÉ

Microbial colonization and development of infections in wounds is a sign of chronicity. The prevailing approach to manage and treat these wounds involves dressings. However, these often fail in effectively addressing infections, as they struggle to both absorb exudates and maintain optimal local moisture. The system here presented was conceptualized with a three-layer design: the outer layer made of a fibrous polycaprolactone (PCL) film, to act as a barrier for preventing microorganisms and impurities from reaching the wound; the intermediate layer formed of a sodium alginate (SA) hydrogel loaded with ampicillin (Amp) for fighting infections; and the inner layer comprised of a fibrous film of PCL and polyethylene glycol (PEG) for facilitating cell recognition and preventing wound adhesion. Thermal evaluations, degradation, wettability and release behavior testing confirmed the system resistance overtime. The sandwich demonstrated the capability for absorbing exudates (≈70 %) and exhibited a controlled release of Amp for up to 24 h. Antimicrobial testing was performed against Staphylococcus aureus and Escherichia coli, as representatives of Gram-positive and Gram-negative bacteria: >99 % elimination of bacteria. Cell cytotoxicity assessments showed high cytocompatibility levels, confirming the safety of the proposed sandwich system. Adhesion assays confirmed the system ease of detaching without mechanical effort (0.37 N). Data established the efficiency of the sandwich-like system, suggesting promising applications in infected wound care.


Sujet(s)
Alginates , Antibactériens , Escherichia coli , Polyesters , Staphylococcus aureus , Infection de plaie , Alginates/composition chimique , Infection de plaie/traitement médicamenteux , Infection de plaie/microbiologie , Staphylococcus aureus/effets des médicaments et des substances chimiques , Escherichia coli/effets des médicaments et des substances chimiques , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Antibactériens/composition chimique , Antibactériens/administration et posologie , Polyesters/composition chimique , Ampicilline/pharmacologie , Ampicilline/usage thérapeutique , Ampicilline/composition chimique , Humains , Hydrogels/composition chimique , Polyéthylène glycols/composition chimique , Animaux , Bandages , Tests de sensibilité microbienne , Souris , Cicatrisation de plaie/effets des médicaments et des substances chimiques
8.
Int J Antimicrob Agents ; 64(1): 107190, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38697579

RÉSUMÉ

BACKGROUND: Severe infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have been reported increasingly over the past few years. Many in-vivo and in-vitro studies have suggested a possible role of intravenous fosfomycin for the treatment of CRAB infections. METHODS: This multi-centre, retrospective study included patients treated with intravenous fosfomycin for severe infections caused by CRAB admitted consecutively to four hospitals in Italy from December 2017 to December 2022. The primary goal of the study was to evaluate the risk factors associated with 30-day mortality in the study population. A propensity score matched analysis was added to the model. RESULTS: One hundred and two patients with severe infections caused by CRAB treated with an intravenous fosfomycin-containing regimen were enrolled in this study. Ventilator-associated pneumonia (VAP) was diagnosed in 59% of patients, primary bacteraemia in 22% of patients, and central-venous-catheter-related infection in 16% of patients. All patients were treated with a regimen containing intravenous fosfomycin, mainly in combination with cefiderocol (n=54), colistin (n=48) or ampicillin/sulbactam (n=18). Forty-eight (47%) patients died within 30 days. Fifty-eight (57%) patients experienced clinical therapeutic failure. Cox regression analysis showed that diabetes, primary bacteraemia and a colistin-containing regimen were independently associated with 30-day mortality, whereas adequate source control of infection, early 24-h active in-vitro therapy, and a cefiderocol-containing regimen were associated with survival. A colistin-based regimen, A. baumannii colonization and primary bacteraemia were independently associated with clinical failure. Conversely, adequate source control of infection, a cefiderocol-containing regimen, and early 24-h active in-vitro therapy were associated with clinical success. CONCLUSIONS: Different antibiotic regimens containing fosfomycin in combination can be used for treatment of severe infections caused by CRAB.


Sujet(s)
Infections à Acinetobacter , Acinetobacter baumannii , Administration par voie intraveineuse , Antibactériens , Carbapénèmes , Fosfomycine , Pneumopathie infectieuse sous ventilation assistée , Sulbactam , Humains , Fosfomycine/usage thérapeutique , Fosfomycine/administration et posologie , Acinetobacter baumannii/effets des médicaments et des substances chimiques , Infections à Acinetobacter/traitement médicamenteux , Infections à Acinetobacter/mortalité , Infections à Acinetobacter/microbiologie , Études rétrospectives , Mâle , Femelle , Antibactériens/usage thérapeutique , Antibactériens/administration et posologie , Sujet âgé , Adulte d'âge moyen , Carbapénèmes/usage thérapeutique , Sulbactam/usage thérapeutique , Sulbactam/administration et posologie , Pneumopathie infectieuse sous ventilation assistée/traitement médicamenteux , Pneumopathie infectieuse sous ventilation assistée/microbiologie , Pneumopathie infectieuse sous ventilation assistée/mortalité , Colistine/usage thérapeutique , Colistine/administration et posologie , Italie , Ampicilline/usage thérapeutique , Ampicilline/administration et posologie , , Sujet âgé de 80 ans ou plus , Association de médicaments , Bactériémie/traitement médicamenteux , Bactériémie/microbiologie , Bactériémie/mortalité , Multirésistance bactérienne aux médicaments
9.
Acta Paediatr ; 113(7): 1694-1700, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38578153

RÉSUMÉ

AIM: To compare the prophylactic efficacy of ampicillin and clindamycin against vertical transmission of group B Streptococcus from mothers to their infants by evaluating the rates of group B Streptococcus colonisation. METHODS: We retrospectively extracted data for mothers who delivered at Showa University Northern Yokohama Hospital between 1 October 2017 and 31 March 2021 and tested positive for antepartum group B Streptococcus, and their infants. The chi-square test was used to compare the rates of group B Streptococcus colonisation, sepsis, and meningitis. We conducted a multivariate logistic regression analysis, including the time interval between membrane rupture and delivery, chorioamnionitis, and maternal intrapartum fever (≥38.0°C). RESULTS: Two hundred fifty-nine mothers and their infants were eligible. Ampicillin and clindamycin were administered to 150 and 109 mothers, respectively. In the ampicillin and clindamycin groups, 12.0% (18/150) and 37.6% (41/109) infants were group B Streptococcus positive, respectively. The rate of group B Streptococcus colonisation among infants was significantly lower in the ampicillin group (p < 0.001). Multivariate regression analysis showed similar results (p < 0.001). No sepsis or meningitis cases were observed in either group. CONCLUSION: Prophylactic efficacy of clindamycin against the vertical transmission of group B Streptococcus is lower than that of ampicillin.


Sujet(s)
Ampicilline , Antibactériens , Clindamycine , Transmission verticale de maladie infectieuse , Infections à streptocoques , Streptococcus agalactiae , Humains , Ampicilline/usage thérapeutique , Clindamycine/usage thérapeutique , Femelle , Transmission verticale de maladie infectieuse/prévention et contrôle , Études rétrospectives , Infections à streptocoques/prévention et contrôle , Infections à streptocoques/transmission , Grossesse , Antibactériens/usage thérapeutique , Nouveau-né , Adulte , Antibioprophylaxie/méthodes , Complications infectieuses de la grossesse/prévention et contrôle , Complications infectieuses de la grossesse/traitement médicamenteux
10.
Infection ; 52(4): 1621-1625, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38488973

RÉSUMÉ

INTRODUCTION: Haemophilus influenzae (HI) is an exceedingly rare cause of infective endocarditis (IE). CASE PRESENTATION/METHODS: We present a case of a 90-year-old female diagnosed with HI-IE involving the native tricuspid valve in the absence of traditional risk factors for right-sided endocarditis. She was treated with a 5-week course of IV Ampicillin from negative cultures and suffered no complications. We also conducted a thorough literature review through PubMed and Google Scholar, which yielded a mere 15 reported cases of HI-IE. RESULTS: Fourteen of the reported HI-IE cases included epidemiological data, showing no gender predominance. The mean age of the subjects was 39.5, with the mitral valve being the most implicated (64%) and tricuspid valve involvement being rare (21%). CONCLUSION: Native tricuspid valve IE is an uncommon entity, especially in the absence of IV drug use. Haemophilus influenzae is an extremely rare cause of IE, with a literature review showing merely 15 reported cases. This article cites the 16th case of HI-IE published in the literature.


Sujet(s)
Antibactériens , Endocardite bactérienne , Infections à Haemophilus , Haemophilus influenzae , Humains , Femelle , Infections à Haemophilus/traitement médicamenteux , Infections à Haemophilus/microbiologie , Infections à Haemophilus/diagnostic , Sujet âgé de 80 ans ou plus , Haemophilus influenzae/isolement et purification , Antibactériens/usage thérapeutique , Endocardite bactérienne/microbiologie , Endocardite bactérienne/traitement médicamenteux , Endocardite bactérienne/diagnostic , Ampicilline/usage thérapeutique , Valve atrioventriculaire droite/microbiologie , Valve atrioventriculaire droite/imagerie diagnostique
11.
Inn Med (Heidelb) ; 65(5): 512-516, 2024 May.
Article de Allemand | MEDLINE | ID: mdl-38459199

RÉSUMÉ

BACKGROUND: Rat bite fever is a rare but potentially fatal bacterial zoonosis. The symptoms can be unspecific, but severe sepsis can be associated with involvement of different organs. CASE REPORT: A 27-year-old homeless man presented with fever, suspected meningitis, acute renal failure, unclear skin lesions as well as joint problems and muscular pain. Bite wounds were not detected. Meningitis could be excluded after lumbar puncture, and there was no evidence of endocarditis as the cause of the skin lesions. After 72 h, growth of Streptobacillus moniliformis in blood cultures was detected. Clinical symptoms were compatible with the diagnosis of rat bite fever. Calculated antibiosis with ampicillin sulbactam and doxycycline led to regression of the symptoms. CONCLUSION: Rat bite fever poses a diagnostic challenge due unspecific symptoms, diverse differential diagnostic options, and challenging microbiological detection. Patient history is of the utmost importance. Due to the rarity of the disease, this case report is intended to raise awareness.


Sujet(s)
Fièvre par morsure de rat , Streptobacillus , Zoonoses , Mâle , Adulte , Fièvre par morsure de rat/diagnostic , Fièvre par morsure de rat/traitement médicamenteux , Fièvre par morsure de rat/microbiologie , Humains , Animaux , Streptobacillus/isolement et purification , Zoonoses/diagnostic , Zoonoses/microbiologie , Zoonoses/transmission , Antibactériens/usage thérapeutique , Doxycycline/usage thérapeutique , Diagnostic différentiel , Rats , Sulbactam/usage thérapeutique , Sulbactam/administration et posologie , Ampicilline/usage thérapeutique
12.
J Infect Dev Ctries ; 18(2): 219-226, 2024 Feb 29.
Article de Anglais | MEDLINE | ID: mdl-38484340

RÉSUMÉ

OBJECTIVE: To investigate the clinical characteristics and prognostic risk factors for Klebsiella pneumoniae bloodstream infections in immunocompetent patients. METHODS: The study included patients with K. pneumoniae bloodstream infection treated in Zhongda Hospital from June 2016 to June 2021. Clinical data and antibiotic susceptibility test results were retrospectively collected and analyzed. Independent risk factors for mortality were screened using the chi-square test and multivariate logistic regression. RESULTS: A total of 152 patients were included in the analysis. In our cohort, 77.6% of patients were older than 60 years, and 80.9% of them had community-acquired infections. The most common complications were type 2 diabetes, hypertension, and stroke sequelae. The proportion of patients with septic shock or abscesses was 34.9% and 25.7%, respectively. There were significant differences in the site of infection, septic shock, and serum levels of procalcitonin, hypersensitive C-reactive protein, D-dimer, creatinine, and lactic acid between survivors and non-survivors (p < 0.05). Multivariate regression analysis showed that hospital-acquired infections, septic shock, length of hospital stay, and creatinine levels were independent risk factors for mortality. Antibiotic susceptibility test results indicated that clinical outcomes varied depending on bacterial sensitivity to ampicillin/sulbactam. DISCUSSION: Klebsiella pneumoniae is a common community-acquired and hospital-acquired bacteria and usually infects older people with complications such as diabetes. Nosocomial infections, length of stay, septic shock, and renal insufficiency are potentially associated with poor prognosis. Bacterial susceptibility to ampicillin/sulbactam affects prognosis.


Sujet(s)
Bactériémie , Infection croisée , Diabète de type 2 , Infections à Klebsiella , Sepsie , Choc septique , Humains , Sujet âgé , Klebsiella pneumoniae , Études rétrospectives , Sulbactam/usage thérapeutique , Créatinine , Bactériémie/microbiologie , Infections à Klebsiella/microbiologie , Facteurs de risque , Antibactériens/usage thérapeutique , Infection croisée/microbiologie , Sepsie/traitement médicamenteux , Ampicilline/usage thérapeutique
13.
J Infect Dev Ctries ; 18(2): 227-234, 2024 Feb 29.
Article de Anglais | MEDLINE | ID: mdl-38484341

RÉSUMÉ

INTRODUCTION: Extensively drug resistant (XDR) strains of the Salmonella lineages have been reported to spread from Africa to South Asia. XDR strains are resistant to fluoroquinolones, chloramphenicol, co-trimoxazole, and ampicillin, resulting in treatment failure. The objectives of this study included the investigation of transmission of S. Typhi lineages and the identification of the potentially contaminated sources of the XDR typhoid outbreak from different urban areas by using molecular techniques. METHODOLOGY: Environmental samples, including food samples, were collected from different towns and the susceptibility of each isolate to the antimicrobial agents was examined. Molecular identification of different Salmonella lineages including S. Typhi, S. Paratyphi A, H58, and XDR was carried out through multiplex PCR. RESULTS AND CONCLUSIONS: A total of 328 environmental samples including raw vegetables, water, and bakery items were collected. More than half of the tested samples (64%) found harboring Salmonella spp. The Salmonella was confirmed through PCR amplification of species-specific markers that showed the presence of S. Typhi (40%), S. Paratyphi A (8%), H58 (7%), and XDR S. Typhi (6%). Raw vegetables had the highest number of Salmonella spp., indicating consumption of raw vegetables as a possible source of salmonellosis. XDR status was also affirmed through phenotypic antimicrobial susceptibility testing.


Sujet(s)
Salmonella typhi , Fièvre typhoïde , Légumes , Fièvre typhoïde/épidémiologie , Fièvre typhoïde/traitement médicamenteux , Ampicilline/usage thérapeutique , Chloramphénicol/usage thérapeutique , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Résistance bactérienne aux médicaments
14.
Clin Lab ; 70(3)2024 Mar 01.
Article de Anglais | MEDLINE | ID: mdl-38469790

RÉSUMÉ

BACKGROUND: This case involves a 28-year-old pregnant woman (39w+2) who was admitted to obstetrics due to abdominal tightness and bacteremia with Gardnerella vaginalis which developed after caesarean section and vaginal myomectomy. METHODS: A blood culture was performed, and the bacteria were identified through mass spectrometry. RESULTS: Mass spectrometry data indicated that the infection bacteria were Gardnerella vaginalis. The patient's temperature returned to normal after oral ampicillin in combination with clindamycin. CONCLUSIONS: Gardnerella vaginalis bacteremia is very rare in clinical practice, and the combination of ampicillin and clindamycin has a good therapeutic effect. This study may provide a reference for the diagnosis and treatment of Gardnerella vaginalis bacteremia.


Sujet(s)
Bactériémie , Myomectomie de l'utérus , Vaginose bactérienne , Femelle , Grossesse , Humains , Adulte , Gardnerella vaginalis , Femmes enceintes , Clindamycine/usage thérapeutique , Césarienne/effets indésirables , Ampicilline/usage thérapeutique , Bactériémie/diagnostic , Bactériémie/traitement médicamenteux , Bactériémie/microbiologie , Vaginose bactérienne/traitement médicamenteux , Vagin
15.
J Antimicrob Chemother ; 79(4): 801-809, 2024 04 02.
Article de Anglais | MEDLINE | ID: mdl-38334390

RÉSUMÉ

OBJECTIVES: To investigate the genomic diversity and ß-lactam susceptibilities of Enterococcus faecalis collected from patients with infective endocarditis (IE). METHODS: We collected 60 contemporary E. faecalis isolates from definite or probable IE cases identified between 2018 and 2021 at the University of Pittsburgh Medical Center. We used whole-genome sequencing to study bacterial genomic diversity and employed antibiotic checkerboard assays and a one-compartment pharmacokinetic-pharmacodynamic (PK/PD) model to investigate bacterial susceptibility to ampicillin and ceftriaxone both alone and in combination. RESULTS: Genetically diverse E. faecalis were collected, however, isolates belonging to two STs, ST6 and ST179, were collected from 21/60 (35%) IE patients. All ST6 isolates encoded a previously described mutation upstream of penicillin-binding protein 4 (pbp4) that is associated with pbp4 overexpression. ST6 isolates had higher ceftriaxone MICs and higher fractional inhibitory concentration index values for ampicillin and ceftriaxone (AC) compared to other isolates, suggesting diminished in vitro AC synergy against this lineage. Introduction of the pbp4 upstream mutation found among ST6 isolates caused increased ceftriaxone resistance in a laboratory E. faecalis isolate. PK/PD testing showed that a representative ST6 isolate exhibited attenuated efficacy of AC combination therapy at humanized antibiotic exposures. CONCLUSIONS: We find evidence for diminished in vitro AC activity among a subset of E. faecalis IE isolates with increased pbp4 expression. These findings suggest that alternate antibiotic combinations against diverse contemporary E. faecalis IE isolates should be evaluated.


Sujet(s)
Endocardite bactérienne , Endocardite , Infections bactériennes à Gram positif , Humains , Ceftriaxone/pharmacologie , Ceftriaxone/usage thérapeutique , Enterococcus faecalis , Ampicilline/pharmacologie , Ampicilline/usage thérapeutique , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Endocardite bactérienne/traitement médicamenteux , Endocardite bactérienne/microbiologie , Endocardite/traitement médicamenteux , Tests de sensibilité microbienne , Infections bactériennes à Gram positif/traitement médicamenteux , Infections bactériennes à Gram positif/microbiologie , Association de médicaments
17.
Eur J Clin Microbiol Infect Dis ; 43(5): 1013-1016, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38416289

RÉSUMÉ

We report a clinical case of a child with an invasive pneumococcal disease caused by two different pneumococcal serotypes that belonged to different sequence types. She was a 15-month-old girl with pneumonia and pleural effusion in which S. pneumoniae colonies with different morphologies grew, one from the blood culture (characteristic greyish appearance) and the other from the pleural fluid (mucoid appearance). The isolate from blood was serotype 22 F (ST698/CC698/GPSC61), while the isolate from the pleural fluid was serotype 3 (ST180/CC180/GPSC12). The patient fully recovered after treatment with intravenous ampicillin followed by oral amoxicillin.


Sujet(s)
Antibactériens , Sérogroupe , Streptococcus pneumoniae , Humains , Streptococcus pneumoniae/isolement et purification , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/génétique , Femelle , Nourrisson , Antibactériens/usage thérapeutique , Infections à pneumocoques/microbiologie , Infections à pneumocoques/traitement médicamenteux , Infections à pneumocoques/diagnostic , Épanchement pleural/microbiologie , Amoxicilline/usage thérapeutique , Ampicilline/usage thérapeutique , Pneumonie à pneumocoques/microbiologie , Pneumonie à pneumocoques/traitement médicamenteux , Pneumonie à pneumocoques/diagnostic , Résultat thérapeutique
18.
Am J Case Rep ; 25: e943030, 2024 Feb 18.
Article de Anglais | MEDLINE | ID: mdl-38368503

RÉSUMÉ

BACKGROUND Actinomycosis is a clinically significant but uncommon infectious disease caused by anaerobic commensals of Actinomyces species, and the incidence of thoracic empyema is rare. We report an extremely rare case of empyema caused by Actinomyces naeslundii (A. naeslundii). CASE REPORT A 39-year-old man presented to our hospital with fever and dyspnea. He had massive pleural effusion and was diagnosed with a left lower-lobe abscess and left thoracic empyema. Thoracic drainage was performed and Ampicillin/Sulbactam was administered for 3 weeks. Four years later, the patient presented with back pain, and chest X-ray showed increased left pleural effusion. After close examination, malignant pleural mesothelioma was suspected, and computed tomography-guided needle biopsy was performed, which yielded a viscous purulent pleural effusion with numerous greenish-yellow sulfur granules. A. naeslundii was identified through anaerobic culture. Thoracoscopic surgery of the empyema cavity was conducted, and Ampicillin/Sulbactam followed by Amoxicillin/Clavulanate was administered for approximately 6 months. No recurrence has been observed for 1 year since the surgical procedure. CONCLUSIONS Actinomyces empyema is a rare condition, and this case is the second reported occurrence of empyema caused by A. naeslundii. The visual identification of sulfur granules contributed to the diagnosis. Long-term antibiotic therapy plays a crucial role in treatment.


Sujet(s)
Empyème pleural , Empyème , Épanchement pleural , Mâle , Humains , Adulte , Sulbactam/usage thérapeutique , Empyème pleural/diagnostic , Actinomyces , Ampicilline/usage thérapeutique , Soufre
19.
Med J Malaysia ; 79(1): 74-79, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-38287761

RÉSUMÉ

INTRODUCTION: Salmonella typhi could infect the intestinal tract and the bloodstream or invade body organs and secrete endotoxins. It is endemic in developing countries. It is increasingly evolving antimicrobial resistance to several commonly used antimicrobial agents. MATERIALS AND METHODS: A cross-sectional study was done at Iraqi Communicable Disease Control Center, where all confirmed cases of Salmonella typhi are reported, for a period 2019-2021. All demographic, epidemiological and clinical characteristics of patients, comorbidities, type of samples, distribution of S. typhi by age and gender, time distribution in each year and profile of bacterial resistance and sensitivity to antibiotics were gathered and analysed. RESULTS: Most samples were taken from blood. The mean age of cases during 2019, 2020 and 2021 was 18.7 ± 6.5, 17.7 ± 14.1 and 17.3 ± 12.8. Males constituted 56.7%, 58.5% and 39.8%, respectively. Some cases had comorbidities. Most cases had headache and fever. Some of them had nausea, diarrhoea, vomiting and epigastric pain. The age and sex were significantly associated with years of reporting. The most months of case reporting were June-July (2019 and 2021), Jan. -Feb. (2020). There was an obvious increase in S. typhi resistance to ceftriaxone (92.2%, 86.1%, 88.8%) and ampicillin (77.1%, 76.9%, 81.27%). There was a gradual increase in sensitivity to tetracycline (83.1%, 88.1%, 94%), cotrimoxazole (86.7%, 86.1%, 92.2%), ciprofloxacin (78.3%, 90.1%, 87.8%) and cefixime (77.7%, 72.3%, 72.7%). CONCLUSIONS: There was a sharp rise in resistance rates of the S. typhi in Iraq (during 2019-2021) to ceftriaxone and ampicillin, while there were highest sensitivity rates to imipenem, aztreonam and chloramphenicol. The following recommendations were made: (1) Improvement of general hygiene and food safety measures. (2) Emphasis on vaccination and surveillance of Salmonella infection. (3) Rational use of appropriate antibiotics through implementation of treatment guidelines. (5) Educate communities and travelers about the risks of S. typhi and its preventive measures.


Sujet(s)
Fièvre typhoïde , Mâle , Humains , Fièvre typhoïde/traitement médicamenteux , Fièvre typhoïde/épidémiologie , Fièvre typhoïde/microbiologie , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Ceftriaxone/usage thérapeutique , Iraq/épidémiologie , Études transversales , Prévalence , Résistance bactérienne aux médicaments , Tests de sensibilité microbienne , Salmonella typhi , Ampicilline/usage thérapeutique
20.
Clin Lab ; 70(1)2024 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-38213202

RÉSUMÉ

BACKGROUND: Gastroenteritis refers to an infection in the stomach and small intestine that may be caused by bacteria, viruses, and other pathogenic agents. Most strains of Escherichia coli (E. coli) in the gastrointestinal system have shared a symbiotic relationship with humans, but some serotypes are pathogenic. This study aimed to identify E. coli pathotypes isolated from stool samples and determine the antibiotic resistance profiles of these pathotypes in the west of Iran. METHODS: The study was conducted on 106 samples of diarrheal feces which were sent to Imam Reza laboratory. First E. coli was detected and then the DNA was extracted. Next, the antibiotic sensitivity test was performed by the disk diffusion method. The E. coli pathotypes were qualitatively detected using the Amplisense Escherichioses-FRT PCR kit after DNA extraction from E. coli isolated in the stool sample. RESULTS: In this study, out of 106 E. coli-positive samples, pathogenic E. coli were detected in 62 samples including 5 samples (8.1%) which only contained the EPEC pathotype, 10 samples (16.1%) contained only the EAEC pathotype, and 12 samples (19.4%) had only the EHEC pathotype. ETEC and EIEC were not isolated from any of the samples. The sensitivity to Meropenem (97%) and Gentamicin (96.2%) showed the highest frequency among the samples. The highest level of resistance was related to Amoxicillin (93.4%) and Ampicillin (78%). CONCLUSIONS: The epidemiological results show that the predominant pathotype among all isolates is EHEC and most antibiotic resistances were related to Amoxicillin and Ampicillin. Finally, a comprehensive molecular diagnosis of E. coli pathotypes, investigation of their incidence, and antibiogram profiles will help to determine better diagnostic and therapeutic measures for managing diarrheal diseases.


Sujet(s)
Escherichia coli entéropathogène , Infections à Escherichia coli , Humains , Antibactériens/pharmacologie , Antibactériens/usage thérapeutique , Infections à Escherichia coli/diagnostic , Infections à Escherichia coli/traitement médicamenteux , Infections à Escherichia coli/épidémiologie , Escherichia coli entéropathogène/génétique , Iran/épidémiologie , Résistance bactérienne aux médicaments/génétique , Diarrhée/microbiologie , Ampicilline/usage thérapeutique , Amoxicilline , ADN
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE